- Trial phase
- Filed/NDA under FDA review (PDUFA January 29, 2027)
- Time to market
- If approved, launch is anticipated in early 2027, shortly after the January 29, 2027 PDUFA date.
- Why 8/10
- The next hard, dated catalyst is the FDA PDUFA target action date of January 29, 2027, roughly 2.5 months from today. Ulixacaltamide is Praxis's lead asset, driving approximately 70% of the company's modeled pipeline value, and the PDUFA represents a binary approval/rejection decision in a large unmet-need market with no currently approved targeted pharmacotherapy.
The next hard catalyst is the PDUFA decision on January 29, 2027, roughly 2.5 months away. An approval would make ulixacaltamide the first FDA-approved targeted pharmacotherapy for essential tremor, a large unmet-need market. A Complete Response Letter would erase most of the company's modeled value. Watch for any FDA AdComm announcement (none currently expected) and for the relutrigine PDUFA on December 27, 2026, which will set the tone for the stock ahead of the ulixacaltamide decision.
Price Chart
Executive Summary
Ulixacaltamide is Praxis Precision Medicines' lead drug candidate, an oral T-type calcium channel antagonist for essential tremor, a movement disorder affecting roughly 7 million Americans with no currently approved targeted pharmacotherapy. Positive Phase 3 Essential3 topline results were announced in October 2025, driving the stock up over 200%. The FDA accepted the NDA in April 2026 with a PDUFA target action date of January 29, 2027, and granted Breakthrough Therapy Designation. No advisory committee meeting is currently expected. The stock trades around $321 with a Strong Buy analyst consensus and a mean price target of $662, implying roughly 106% upside. However, the stock is highly concentrated on this single binary catalyst (about 70% of modeled pipeline value), and tolerability issues from the Phase 3 data pose commercial risk.
How It Works
Ulixacaltamide is an oral medication that blocks T-type calcium channels in the brain. These channels are involved in generating the abnormal rhythmic electrical activity that causes essential tremor (uncontrollable shaking, typically of the hands). By blocking them, the drug aims to reduce tremor severity and improve patients' ability to perform daily activities like eating, writing, and drinking.
Trial Status
Two pivotal Phase 3 Essential3 studies completed with positive topline results (both met primary endpoint mADL11 at Week 8 with p<0.0001). NDA submitted in early 2026 and accepted by FDA in April 2026. Breakthrough Therapy Designation granted December 2025. A transdermal formulation is also in early development via a collaboration with Remagine Labs.
The Two-Sided Case
Upcoming Catalysts
- PDUFA target action date: January 29, 2027 (FDA decision on approval)
- Relutrigine PDUFA: December 27, 2026 (sister drug, could affect sentiment)
- Potential FDA advisory committee meeting (none currently expected, but could be scheduled)
- Commercial launch preparations and Investor Day (November 12, 2026 already held)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Praxis Precision Medicines, Inc. 8-K PRAX ·Originating report